Loading...
•
Dec 31, 2019
Orthofix Q4 2019 Earnings Report
Reported financial results for the fourth quarter and fiscal year.
Key Takeaways
Orthofix Medical Inc. reported net sales of $121.5 million, EPS of $0.60, and adjusted EPS of $0.51 for the fourth quarter of 2019.
Net sales increased by 0.3% compared to the prior year period, and 0.9% on a constant currency basis.
Kevin Kenny joined as Global Spine President.
FDA approved the next generation Bone Growth Therapy patient monitoring app STIM onTrack 2.1.
M6 cervical disc in the U.S. revenue outpaced expectations.
Orthofix
Orthofix
Orthofix Revenue by Segment
Revenue by Segment
Bone Growth Therapies Revenue
CapyFin.comSpinal Implants, Biologics and Enabling Technologies Revenue
CapyFin.comGlobal Spine Revenue
CapyFin.com Forward Guidance
The Company expects net sales between $467.0 million and $477.0 million, Adjusted EBITDA between $65.0 million and $68.0 million, and Adjusted EPS between $1.00 and $1.10 for the year ending December 31, 2020.
Positive Outlook
- Net sales are expected to increase by 1.5% to 3.7% year-over-year.
- Net sales are expected to increase by 2.3% to 4.5% on a constant currency basis.
- First Quarter 2020 Net sales between $106.0 and $109.0
- First Quarter 2020 Adjusted EBITDA between $10.5 and $11.5
- First Quarter 2020 Adjusted EPS between $0.09 and $0.12
Challenges Ahead
- Adjusted EBITDA is expected to decrease by 14.2% to 10.2% year-over-year.
- Adjusted EPS is expected to decrease by 32.0% to 25.2% year-over-year.
- First Quarter 2020 Net sales expected to decrease of 2.9% to 0.1% on a reported basis
- First Quarter 2020 Net sales expected to decrease of 1.0% to an increase of 1.7% on a constant currency basis
- First Quarter 2020 Adjusted EBITDA expected to decrease of 33.0% to 26.6%
Revenue & Expenses
Visualization of income flow from segment revenue to net income